We outline an integrative approach to extend the boundaries of molecular cancer epidemiology by integrating modern and rapidly evolving "omics" technologies into state-of-the-art molecular epidemiology. In this way, one can comprehensively explore the mechanistic underpinnings of epidemiologic observations in cancer risk and outcome. We highlight the exciting opportunities to collaborate across large observational studies and to forge new interdisciplinary collaborative ventures.
No takes yet. Share an insight, caveat, or question.
Spitz et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: